←Back to Expert Scholars
Translational Medicine / 转化医学MET Exon 14 Skipping Alterations
Paul Paik
MD
🏢Memorial Sloan Kettering Cancer Center🌐USA
Associate Attending
52
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Paul Paik has made key contributions to understanding MET exon 14 skipping biology and clinical outcomes. He was a lead investigator on the GEOMETRY mono-1 trial that established capmatinib for this indication. His work on MET amplification as a resistance mechanism has informed combination therapy strategies.
Share:
🧪Research Fields 研究领域
MET exon 14 skipping
Capmatinib
NSCLC rare mutations
Biomarker development
Thoracic oncology
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Paul Paik 的研究动态
Follow Paul Paik's research updates
留下邮箱，当我们发布与 Paul Paik（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment